Concepedia

Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial

Yungan Tao, J. Biau, X.S. Sun, Clément Sire, Laurent Martin, M. Alfonsi, J.B. Prevost, A. Modesto, C. Lafond, J.M. Tourani,

Annals of Oncology · 2022 · 177 citations · 17 references

DOIFull text

Open access

Concepts

References

17

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram et al. · CA A Cancer Journal for Clinicians · 2018 · 87.7K citations · Full text

, , +16

Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck

James A. Bonner, Paul M. Harari, J. Giralt et al. · New England Journal of Medicine · 2006 · 5.1K citations · Full text

, , +13

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

Robert L. Ferris, George R. Blumenschein, Jérôme Fayette et al. · New England Journal of Medicine · 2016 · 5.1K citations · Full text

, , +5

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Burtness, Kevin J. Harrington, Richard Greil et al. · The Lancet · 2019 · 3.2K citations · Full text

, , +11

Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients

Jean‐Pierre Pignon, Aurélie Le Maître, E. Maillard et al. · Radiotherapy and Oncology · 2009 · 3K citations

, , +9